adult ADD education

June 3 2017

Dr. David W. Goodman Interview by NPR Morning Edition May 29, 2017

David W. Goodman, MD Clinician Articles, Doctor's Blog, Media Interviews Online Articles, Patient Education adult ADD education, Adult Attention Deficit Disorder, Adult Attention Deficit Hyperactivity Disorder, David W. Goodman MD, National Public Radio and ADD, National Public Radio and adult ADD, National Public Radio and adult ADHD, NPR and ADD, NPR and ADHD

National Public Radio recently posted my interview (click on “Heard on Morning Editon”) from April 2017 about a research publication reviewing a revised adult ADHD screener developed in coordination with the World Health Organization. What the journalist didn’t know at the time that I will share with you is that I was a pre-publication peer reviewer on this study. That means I was very knowledgeable about the details of the study and had offered my critique to the publisher prior to publication. For additional background on this screener, see my previous blog.

Now, let’s address the audio quotes.

Dr. Lawrence Diller says “I don’t know what ADHD is anymore” referring to changes over the past 3 decades of changes in the Diagnostic and Statistic Manual used to establish diagnostic criteria for psychiatric disorders. I’m surprised by his comment given 20+ years of international research (tens of thousands of scientific publications from around the world) that has better defined the symptoms and impairments of ADHD. It is this research that has contributed to better defining ADHD in children and the progression of ADHD into adulthood therefore accounting for the evolution of changes in the current DSM 5. The diagnosis of ADHD is not based on a cluster of symptoms at one point in time. The diagnosis is based on the cluster of symptoms as they impair the person over the course of their life. Everyone has some inattention and distractibility at some point but few have the symptoms since childhood that have never gone away and are observed by others as a problem.

How about Alan Schwarz’s comments who disqualifies published peer reviewed science by indicting the experts and researchers who have conducted research with and without pharmaceutical support. To indict the international ADHD research community would be to suggest an international conspicacy of hundreds, if not thousands, of physicians and psychologists across 7 continents. This is a basic journalistic method (shoot the messager) to distract readers from the merits of an issue. I have personal experience with Mr. Schwarz who took to indicting me in his New York Times article when he conveyed to readers that I was advocating teaching primary care physicians how to diagnosis ADHD based on a short video clip. What he deliberately chose not to include in his article was the fact that the video was a visual representation accompanying a 2500 word, 168 scientific references, and peer reviewed article. Focused only on his agenda to act as “educator” to save the “victims” of ADHD medications from the “villians” of doctors, he deliberately misrepresented information for his self-serving purposes.

So, I’ll leave you with my saying, “The credibility of information is dependent on intent of the provider”. A salesperson gives you only information he/she wants you to have to close the sale. An educator gives you information so that your interest is best served first. You need to carefully discern this for yourself.

I will continue to present science in the halls of opinions.

Thank you for your interest….and focused attention.

David W. Goodman, M.D., FAPA

March 12 2016

Dr. David W. Goodman ADHD in older adults U.S. News and World Report March 2016

David W. Goodman, MD Doctor's Blog, Media Interviews Online Articles, Patient Education ADD in older adults, ADHD in older adults, adult ADD, adult ADD diagnosis, adult ADD education, adult ADHD diagnosis, Adult Attention Deficit Disorder, Adult Attention Deficit Hyperactivity Disorder, David W. Goodman MD, help for adult ADD, help for adult ADHD

Since the recent publication of our literature of published research on ADHD in adults over age 50, several news outlets have been interested in bring this subject to the public eye. ADHD in adults persists throughout one’s life. It does not go away because you got your AARP card or Medicare benefits.

Because I believe in the importance of accurate diagnosis and effective treatment for ADHD regardless of age, I wrote an editorial piece that U.S. News and World Report published online on March 7, 2016. This article was picked up by several news (Yahoo News) and professional organizations (American Professional Society for ADHD and Related Disorders – an organization of international clinicians and researchers, and the National Resource Center-a CDC funded organization affiliated with Children and Adults with ADHD Association CHADD).

For most people with ADHD, it is a lifelong condition to be understood, appreciated, respected, and treated effectively. Quality of function and life are greatly effected regardless of your age. I always encourage people with lifelong symptoms of ADHD to get a competent evaluation and learn more about managing these symptoms to improve daily functioning.

January 27 2016

Dr. David W. Goodman interviewed by WOSU (NPR) on Adult ADHD January 26, 2016

David W. Goodman, MD Doctor's Blog, Media Interviews Online Articles, Patient Education ADD in older adults, ADHD in older adults, adult ADD, adult ADD diagnosis, adult ADD education, adult ADD treatment, adult ADHD diagnosis, Adult Attention Deficit Disorder, Adult Attention Deficit Hyperactivity Disorder, David W. Goodman MD

It appears that the topic of ADHD in older adults is catching some attention. I was invited by Ann Fisher of WOSU Radio (NPR affiliate) in Columbia, Ohio to discuss adult ADHD especially in older adults. The host, Ann, asked insightful questions about identification and diagnosis in older adult and how that’s different from younger adults and children. We also covered treatment options including medication and cognitive behavioral therapy.

I am very excited that some media outlets have decided that ADHD in older adults is an opportunity to increase public awareness that “ADHD is not just for kids.”

I invite you the listen to the 20 minute interview. You can find it here. On the time scroll bar, move it to 14:40 minute mark to listen.

David W. Goodman, M.D.

October 13 2015

The New York Times: Older Adults with ADHD

David W. Goodman, MD Doctor's Blog, Media Interviews Online Articles, Patient Education ADD and geriatrics, ADD in older adults, ADHD and geriatrics, ADHD in older adults, adult ADD, adult ADD diagnosis, adult ADD education, adult ADD treatment, adult ADHD, adult ADHD treatment, Adult Attention Deficit Disorder, attention deficit disorder, CHADD, David W. Goodman MD, help for adult ADD, help for adult ADHD, The New York Times ADD

On September 30, 2015, The New York Times ran an article in the Tuesday Science section on ADHD in older adults. I was interviewed for the article and discussed a former patient age 73 who was first diagnosis with ADHD by me and successfully treated. The article is an introduction into an important clinical area for ADHD heretofore ignored. As we discovered, 60% of children will continue to have ADHD symptoms to an impairing degree into adulthood. The presumption is that ADHD in adults will simply continue throughout one’s life. However, the research is only just accumulating to support this assumption. The largest collection of research in this age group is published by my colleagues in Amsterdam and additional research from other research groups around the world.

Early this year I wrote an article for CHADD’s Attention Magazine on issues related to diagnosis and treatment of ADHD in older adults. The diagnostic issues and treatment considerations in older adults are more complex. In brief, diagnosis needs to consider medical illnesses, medications, history of head trauma, and other medical illness that worsen thinking ability. Treatment consideration are complicated by the presence of medications and medical illnesses that might limit the use of ADHD medications. Older patients and families considering an evaluation for possible ADHD should see a psychiatrist or mental health professional who has expertise and experience treating adults with ADHD.

Remember, while attentional changes occur in those of us over age 50, the cornerstone for the diagnosis of ADHD is the presence of symptoms since childhood that are relatively chronic and unchanged over one’s life and that these symptoms cause impairment in daily functioning. A comprehensive evaluation of all possible psychiatric and medical is critical for the accuracy of the diagnosis.

David W. Goodman, M.D., FAPA

April 20 2015

Arbitrary medication denials leads to restriction of optimal treatment

David W. Goodman, MD Doctor's Blog, Patient Education ADD medication, ADD medication denial, ADD medication shortage, ADHD medication, ADHD medication denial, adult ADD education, adult ADD treatment, Adult Attention Deficit Disorder, Adult Attention Deficit Hyperactivity Disorder, attention deficit disorder, David W. Goodman MD

In my periodic entries of insurance companies’ denial of ADHD medication dosing, I offer you this recent example.

A female in her late 20s treated for ADHD with a combination of Adderall XR and Strattera. Strattera adds a benefit for her executive function not optimized with Adderall XR. I carefully dosed the Strattera upward and suggested increase to 120 mg daily.

Well, the folks at BlueCross Northeastern Pennsylvania denied the dose “As per the FDA recommended dosing guidelines for Strattera in adults the maximum dose is 100 mg per day.” Correctly stated per the package insert for Strattera. “There are no data that support increased effectiveness at higher doses. Therefore medical necessity for 120 mg of Strattera per day has not been met.”

This last statement is a misrepresentation of the purpose of a drug package insert. In fact, the adult registration trial for Strattera submitted to the FDA lists the dose that was used as up to 120 mg daily. Registration trials are designed for the purpose of seeking drug approval for a specific disease state. This research DOES NOT answer the question “If the patient is suboptimally treated with x dose, will they improve further with a higher dose?” So the logic of their denial is a misrepresentation of research for the sole purpose of constricting treatment and conserving money, in my opinion.

Yet more damage is done with these letters. People reading these letters may think the doctor is over-dosing them and not considering safety issues. This is simply not true since safety data on medications are routinely undertaken at much higher doses. There was no unusual safety concern with Strattera at 120 mg daily in the adult registration trial.

It is unfortunate that I find myself blogging about the denial of medication authorizations for my patients who clearly need better outcomes from their medications. While these companies have set up appeal processes, this tends to administratively time consuming without any guarantee that the medical necessity and logic of the dose request will be reviewed with the patient’s interest in mind.

So, what can YOU do if this happens to you? Here are the steps:

1. Call the insurance company and respectfully explain why you need your medicine. If the person is unresponsive, ask to speak to supervisor. If you don’t get to speak to someone with authority, ask if the conversation is being recorded and tell them to “tag” the audio file so that the State Insurance Comissioner’s Office with be able to listen to the audio file. Now, write down the date and time.

2. File a complaint with your state insurance commissioner’s office. You can find the contact information online by searching “<your state> insurance commissioner office”. In your complaint, which should only be one page (no reads anymore), state your brief history of medication history and why it is necessary to have the new dosing authorized for coverage. Write that you spoke with the insurance on what date and time.

In my experience, more often than not, you’ll be getting your approval. However, no guarantees. Good luck.

February 4 2015

Deceptive herbs and supplements

David W. Goodman, MD Doctor's Blog, Patient Education adult ADD, adult ADD education, adult ADD treatment, Adult Attention Deficit Disorder, Adult Attention Deficit Hyperactivity Disorder, David W. Goodman MD, Herbs for ADD, Herbs for ADHD, Supplements for ADHD, The New York Times ADD

You might think you’re exercising good judgment by enhancing your health and wellbeing by taking herbs and supplements. While the scientific research with replicated studies is limited, the nutraceutical companies have spent billions promoting their use. Yet now, the real problem is uncovered. The New York Times recently published a story on a investigation into herbs and supplements and found several companies whose products sit on shelves at national pharmacy chains don’t contain the ingredient on the label. UGH. Feeling trick and swindled. You bet. Read the full story here.

While I don’t discourage my patients from pursuing complementary and alternative treatments, understand that regulatory oversight and scientific research is critical in determining the real utility of treatments. Without this, marketing under the guise of education becomes the detrimental order of the day.

Thank you for your interest.

January 22 2015

ADHD adult scholarship for higher education

David W. Goodman, MD Patient Education adult ADD education, Adult ADD money for school, Adult ADD student scholarship, Adult Attention Deficit Hyperactivity Disorder, David W. Goodman MD, help for adult ADD, help for adult ADHD

For those of you who follow my blog and others who have stumbled upon it, I wanted to bring this opportunity to your attention. Shire Pharmaceutical annually provides these scholarships to help students with ADHD get ahead. If you are interested and eligible, please look into this.

The 2015 Scholarship program will award $2,000 and one year of ADHD coaching services* to each of 50 recipients in the United States. Adults with ADHD who are pursuing higher education are encouraged to apply.

Deadline: February 18, 2015

Students may apply and learn more at ShireADHDScholarship.com.

Scholarship Questions? Please call 1-855-474-7432

Who Can Apply

The scholarship program is for legal residents of the United States who:

✔	have been diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)
✔	are accepted to or will be enrolled in a 2- or 4-year undergraduate program** at an accredited college, university, trade school, technical school, or vocational school located in the United States
✔	are under the care of a licensed health care professional for ADHD

Void where prohibited by law. Contest is subject to all federal, state, and local laws, and full rules and regulations.

*Coaching services provided through the Edge Foundation.

January 4 2015

Insurance companies routinely denying higher stimulant doses

David W. Goodman, MD Doctor's Blog, Patient Education ADD medication, ADHD medication, adult ADD education, David W. Goodman MD, Insurance deny for ADHD medications

Almost everyday insurance companies request pre-authorization for stimulant medication for my patients. While many of these requests are approved, many others are not. One obstacle to approval is stimulant dosing. Insurance companies routinely deny coverage for any stimulant dose that exceeds FDA drug label maximum dose. You might believe this is a safety issue and insurance companies are serving you well. I’d like to believe this too. Unfortunately, their decisions are often a guise for cost savings.

In order for you to understand the process, you need to know how the FDA approves the dosing of medication that it approved for a disease/disorder. Let’s take Concerta for example. The registration trial submitted to the FDA was conducted in the U.S. (Adler L, et al) with another trial conducted in German. The U.S. trial for adults had a dosing started at 36 mg in the morning and could be adjusted up to 108 mg in the morning if the subject had not achieved a predetermined improvement level. The FDA approved Concerta 72 mg as the maximum daily dose in adults. Why? Didn’t you say the trial went to 108 mg a day?

Yes, I did. The FDA decided that the higher doses (90 and 108 mg daily) didn’t produce any greater improvement than 72 mg daily. However, the trial was not designed to answer the question “If you don’t response to 72 mg, would your ADHD symptoms decline with 90 or 108 mg?”. Well then, of the subjects in the trial, what was the distribution of doses amongst all the adult subjects? (Remember, the researcher could increase Concerta dose if the subject hadn’t improved to a defined threshold on an ADHD rating scale)

Dose(mg) % of subjects

36 34%

54 15%

72 18%

90 15%

108 21%

So, you’ll notice that 36% (15+21) of adult subjects needed a dose over the FDA max daily dose. That’s 1 out of 3 subjects. Imagine that you are that patient whose ADHD needs a higher dose. Imagine that your doctor, unfamiliar with this research, tells you he can’t prescribe at doses higher than FDA approved max daily doses. Imagine that your insurance company denies what would otherwise be an effective dose. Imagine that you believe that the FDA max dose is related to safety (it’s not in this case). Imagine that the insurance company uses language to intimate safety concern.

The outcome of this imagination? UNDERTREATMENT. Persistent symptoms and daily impairments.

I provide this information so that my patients are educated about the state of the art for ADHD treatment and how to understand the avalanche of information available. Make the distinction between being informed by information and being educated by information.Being informed means having access to the information. Being educated means you understand how to interpret the information. The internet provides the former, I hope your physician provides the later.

September 10 2014

SavRx disrupts effective ADHD treatment

David W. Goodman, MD Clinician Articles, Doctor's Blog, Patient Education ADD medication, ADHD medication, adult ADD education, coverage for stimulants, Denial for stimulants, help for adult ADD, help for adult ADHD, Insurance ADD stimulants, Insurance ADHD stimulants, Insurance and stimulants, Sav-Rx

With an increasing number of adults being nearly diagnosed with ADHD, the expense of ADHD medications for insurance companies has escalated. While the annual prescription increase for childhood ADHD is less than 3%, the ADHD prescription market is growing at approximately 10% per year. As a result of this change, companies are under increased pressure to reduce their pharmacy expense. While this issue is certainly not limited to ADHD medication, my patients are finding the course of the medication treatment disrupted by insurance companies obstructionistic prior approval requests for long-acting stimulant medications.

Patients and their treating physicians may struggle for some time to find the most effective individualized medication dose that produces an optimal reduction in symptoms with tolerable side effects. Patients have recently found insurance companies changing their coverage of authorized medications. That means, that despite prior approval for your current medication, the new coverage change may no longer authorize the medication and/or dose. This is becoming extremely disruptive to my patients finding themselves forced to change medication because of high deductibles, leaving them paying hundreds of dollars a month for their prior effective medication.

To give you a specific example, SavRx, a prescription management service in Fremont, Nebraska, informed my patient who has been treated with Adderall XR 80 mg in the morning for the past six months that the coverage for this was no longer available to her, despite the fact that it had been approved by the previous pharmacy management company. Having submitted the documentation of effective treatment for months, SavRx is still not approving her optimal dose.

My recent experience indicates that this approach to medication authorization is increasing in frequency across several companies. I will continue to post blogs giving examples from other companies.

My suggestion to patients who encounter this issue with their treatment is to call your insurance company and complain about your specific case. The insurance companies may not be aware of what is happening and they certainly don’t want unhappy subscribers, let alone bad public press. We will soldier on.

July 16 2014

Reliable ADHD information

David W. Goodman, MD Doctor's Blog, Patient Education ADD experts, ADD life issues, ADD medication, ADHD and women, ADHD experts, ADHD life issues, ADHD medication, adult ADD, adult ADD diagnosis, adult ADD education, adult ADD experts, adult ADHD, adult ADHD experts, adult ADHD treatment, Adult Attention Deficit Disorder, Adult Attention Deficit Hyperactivity Disorder, attention deficit disorder, David W. Goodman MD, Disruptive behaviour and ADHD, Executive dysfunction in ADD, Executive dysfunction in ADHD, help for adult ADD, help for adult ADHD, Life Skills and ADHD, Relationship and ADD, Relationships and ADHD, Sex and ADHD

If you’re reading this blog, you are one of the millions of people who now use the Internet to gain information on medical issues. In a recent survey of consumers, this is where people are looking for medical information.
Most accessed online resources:
53% web M.D.
22% Wikipedia
19% health magazines and websites
16% advocacy group websites
12% YouTube
10% Facebook
10% blocks
9% Pharma company websites
(results from third annual national consumer survey by Makovsky Health and Kelton, 2014)

I would like to take this opportunity to direct your attention to the attitude magazine website that has a large number of webinars from noted academic and professional experts in ADHD. For many with ADHD it’s often easier to watch a video on a specific ADHD topic then to read a book. While many with ADHD can sit and read for extended periods of time, it always struck me as odd that clinicians referred patients to books knowing their ability to sustain attention would be limited, especially in the evening when it medication affect us dwindled.

Explore the webinars on this site as a can be extremely helpful. On this blog site, I will continue to direct my patients in readers to reliable sources of information and clinical insights from my practice not available elsewhere.